(Q28327140)

English

Phosphodiesterase III inhibition or adrenoreceptor stimulation: Milrinone as an alternative to dobutamine in the treatment of severe heart failure

scientific article published on June 1, 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Phosphodiesterase III inhibition or adrenoreceptor stimulation: Milrinone as an alternative to dobutamine in the treatment of severe heart failure (English)

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

0 references

1 reference

based on heuristic

inferred from title

Cardiology and cardiovascular medicine

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

author name string

G. Mager

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1852090

10 December 2022

R. K. Klocke

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1852090

10 December 2022

A. Kux

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1852090

10 December 2022

H. W. Höpp

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1852090

10 December 2022

H. H. Hilger

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1852090

10 December 2022

language of work or name

0 references

publication date

1 June 1991

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

full work available at URL

https://api.elsevier.com/content/article/PII:0002870391908345?httpAccept=text/xml

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

https://api.elsevier.com/content/article/PII:0002870391908345?httpAccept=text/plain

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

121

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

6 Pt 2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

1974-1983

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure

1

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse.

2

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

[Combination of dopamine and dobutamine in the differential therapy of acute and chronic myocardial failure]

3

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Drugs five years later. Dobutamine

4

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Myocardial metabolic and hemodynamic effects of dobutamine in heart failure complicating coronary artery disease

5

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock

7

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy

8

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Dobutamine in chronic ischemic heart failure: Alterations in left ventricular function and coronary hemodynamics

9

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

The effect of dobutamine on myocardial performance and high-energy phosphate metabolism at different stages of heart failure in cardiomyopathic hamsters: a 31P MRS study

10

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Subsensitivity of beta responses during therapy with a long-acting beta-2 preparation

11

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure

12

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Catecholamine-induced subsensitivity of adenylate cyclase associated with loss of beta-adrenergic receptor binding sites

13

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Tolerance to dobutamine after a 72 hour continuous infusion

15

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Intravenous use of enoximone.

19

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Comparison of acute hemodynamic response to dobutamine and intravenous MDL 17,043 (enoximone) in severe congestive heart failure secondary to ischemic cardiomyopathy or idiopathic dilated cardiomyopathy

20

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Intravenous use of amrinone for the treatment of the failing heart

22

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study.

24

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure

25

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure.

26

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone

27

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts

28

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure

29

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors

30

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure

32

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy

33

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition

34

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

36

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure

38

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure

40

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Identifiers

10.1016/0002-8703(91)90834-5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28327140&oldid=1787339865"